Hepius tirzepatide 500mcg CAS: {2023788-19-2

* Tirzepatide (Suav lub npe: Tirzepatide) yog ib qho tshiab peptide tshuaj tam sim no tsim thiab ua lag luam los ntawm Eli Lilly raws li lub npe **Mounjaro**. **HEPIUS** tej zaum yuav yog lub npe tsis raug cai lossis cov npe channel uas cuam tshuam nrog Tirzepatide (tseem tos kev pom zoo). Nov yog cov ntsiab lus hais txog Tirzepatide:

### ** 1. Cov Tshuaj Qhia Txog Yeeb Nkab **

Tirzepatide yog ob lub agonist uas ua haujlwm ib txhij ntawm ob lub incretin receptors:

- **GLP-1 (Glucagon-zoo li peptide-1) receptor**

- ** GIP (glucose-dependent insulin-tso polypeptide) receptor **

Qhov kev ua dual me ntsis no muab rau cov kev tswj ntshav cov ntshav qab zib thiab kev tswj kom hnyav.

### ** 2. Lub cev thiab tshuaj lom neeg **

- **Molecular qauv**: Tirzepatide yog ib qho hluavtaws peptide uas muaj 39 amino acid residues txuas rau nws cov caj qaum los ntawm fatty acid chains kom ntev cov tshuaj ib nrab-lub neej.

- ** Molecular hnyav**: Kwv yees li 4813.6 Da (Daltons).

- ** Solubility **: Cov tshuaj no feem ntau yog tsim nyob rau hauv daim ntawv ntawm cov tshuaj aqueous rau kev txhaj tshuaj subcutaneous.

- ** Tshav **: Feem ntau tsis muaj xim lossis lub teeb daj pob tshab kua.

### ** 3. Pharmacokinetics **

- ** DOSAGE **: Tirzepatide yog muab los ntawm kev txhaj tshuaj hauv qab daim tawv nqaij, feem ntau ib zaug ib lub lim tiam.

- Pib koob tshuaj: **2.5 mg/lub lim tiam**

- koob tshuaj tu ib txwm: **5-15 mg/lub lim tiam** (hloov raws li tus neeg mob kam rau ua thiab kho cov hom phiaj).

- ** Ib nrab-lub neej **: ** Kwv yees li 5 hnub (120 teev) **. Nws cov khoom siv ntev ua ib zaug-txhua lub lim tiam tau.

**Metabolism thiab excretion**:

- Feem ntau metabolized los ntawm proteases.

-Txhais cov khoom lag luam ntawm cov tshuaj tau tawm hauv cov zis thiab quav.

### 4. Mechanism ntawm Action **

Tirzepatide activates cov painways hauv qab no ntawm GLP -1} thiab gip receptors:

1. **Cov ntshav qab zib tsawg**:

- Txhawb nqa insulin secretion los ntawm pancreatic cells (glucose-dependant).

- inhibits lub zais cia ntawm glucagon los ntawm pancreatic alpha hlwb.

- Ncua lub plab zom mov thiab txo cov ntshav qab zib rov qab.

2. ** Poob phaus **:

- Txo cov zaub mov noj kom tsawg los ntawm kev txhawb nqa qab los ntawm cov khoom noj kom muaj feem xyuam nrog cov tshuab hluav taws xob.

- Ua kom muaj kev kub leeb ntxiv.

### ** 5. Cov ntaub ntawv kho mob **

1. ** Hom 2 Ntshav Qab Zib Mellitus (T.DM) **: Tirzepatide tau pom zoo los txhim kho Glycemic tswj, tshwj xeeb tshaj yog rau cov neeg mob glyotherapy lossis kev kho kev kho mob.

2. ** tswj qhov hnyav** (tseem nyob rau hauv kev kawm): Tirzepatide muaj qhov hnyav hnyav heev hauv cov neeg rog lossis rog, thiab nws cov lus qhia tau nthuav dav zuj zus.

### 6. Kev kho lub voj voog **

- Feem ntau hloov kho raws li tus neeg mob ib txwm muaj, ** Theem pib yog 4 lub lis piam **, thiab tom qab ntawd maj mam nce mus rau lub hom phiaj tshuaj.

- Hoob ntawm kev kho mob feem ntau kav ntawm 6 xyoo, thiab cov ntshav qab zib, qhov hnyav, thiab lwm yam. Xav tau saib xyuas tsis tu ncua.

### ** 7. Cov tshuaj tiv thaiv tsis zoo thiab ceev faj **

1. **Cov tshuaj tiv thaiv tsis zoo**:

- Cov tsos mob plab zom mov: xeev siab, ntuav, raws plab, cem quav.

- Hypoglycemia (feem ntau tshwm sim thaum siv nrog rau lwm cov tshuaj txo cov piam thaj).

- Tsawg qab los noj mov.

2. ** Qhov hnyav tab sis tsis tshua muaj kev cuam tshuam ":

- Pancreatitis.

- Kab mob gallbladder.

- Kev pheej hmoo ntawm cov qog c-cell c-cell (pom hauv kev tshawb fawb tsiaj).

3. ** Tej yam me me **:

- Tus kheej lossis tsev neeg keeb kwm ntawm medullary thyroid cancer.

- Cov neeg mob muaj keeb kwm ntawm ntau endocrine noppry syndrome hom 2.

### ** 8. Cov ntaub ntawv tshawb fawb soj ntsuam **

- Hauv ntau qhov kev sim tshuaj (SURPASS series ntawm kev tshawb fawb), Tirzepatide tau pom tias muaj kev tswj hwm cov ntshav qab zib thiab poob phaus, uas zoo dua rau GLP-1 agonists (xws li semaglutide).

- ** Cov ntaub ntawv poob phaus **: Cov neeg mob hauv pab pawg siab (15 mg / lub lim tiam) ua tiav qhov hnyav ntawm qhov hnyav ntawm ntau dua 20%.

### ** 9. Kev ceev faj rau kev siv **

- ** Kev xaiv chaw ntawm chaw **: Feem ntau lub plab, ncej puab lossis sab caj npab, lub vev xaib yuav tsum tau tig.

- **Storage condition**: Khaws cia txias (2-8 degree), tsis txhob khov.

* Tirzepatide, nyob rau hauv lub npe HEPIUS, yog ib hom tshiab ntawm cov tshuaj txo cov piam thaj, feem ntau yog siv los kho hom 2 mob ntshav qab zib. Nws kuj tau pom tias muaj peev xwm kho cov teebmeem ntawm kev rog thiab metabolic syndrome hauv kev tshawb fawb soj ntsuam. Cov hauv qab no yog cov lus piav qhia ntxaws ntxaws ntawm cov tshuaj siv cov pej xeem, txoj hauv kev ua haujlwm, thiab kev siv thiab ntau npaum li cas:

### **Cov neeg tuaj saib xyuas**

1. **Patients with type 2 diabetes**: Tirzepatide is mainly used to improve blood sugar control in patients with type 2 diabetes, especially for those patients who cannot adequately control their blood sugar through diet control and exercise.

2. ** Cov neeg rog lossis rog rau cov kab mob nrog cov kab mob metabolic ** (nyob rau hauv kev tshawb fawb): Cov neeg no tuaj yeem siv rau cov neeg rog lossis rog dhau.

3. **Cov neeg mob ntshav qab zib muaj kev pheej hmoo ntawm cov kab mob plawv**: Cov kev tshawb fawb soj ntsuam tau pom tias Tirzepatide tuaj yeem pab txhim kho cov kab mob plawv metabolic thiab tshwj xeeb tshaj yog rau cov neeg mob uas muaj kev pheej hmoo siab.

### ** Nws ua haujlwm li cas **

Tirzepatide yog ib tug **dual agonist** nrog ib tug tshwj xeeb thiab complex mechanism ntawm kev txiav txim:

1. ** VAJLIM GLP -1} thiab gip receptors **:

- ** GLP {-1 Cov piam thaj ((lawb tawm ntawm cov kua txob hauv qab zib

- ** QIP RECeptor ** (cov tshuaj pleev roj qab zib-roulin-tso cov khoom lag luam mexypolic)

2. Xam ob qho txiaj ntsig metabolic ":

- Txo cov piam thaj hauv siab thiab txo cov ntshav qab zib sai.

- Txhawb nqa kev txhim kho ntawm pancreatic -cell muaj nuj nqi thiab ncua kev mob ntshav qab zib.

-Suppresses qab los noj mov thiab txhawb zog siv zog, ua rau poob phaus.

### ** Kev Siv thiab Dosage **

1. ** Daim foos thiab cov lus qhia tshwj xeeb **:

- Tirzepatide feem ntau yog muab raws li kev txhaj tshuaj subcutaneous thiab muaj nyob rau ntau yam tshuaj noj ntau yam (piv txwv li 2.5 mg, 5 mg, 15 mg, thiab lwm yam).

2. ** Pib koob tshuaj **:

- Qhov pib koob tshuaj feem ntau yog 2.5 mg subcutaneously ib zaug ib lub lim tiam.

- Tom qab 4 lub lis piam, maj mam nce mus rau lub hom phiaj dose (piv txwv, 5 mg / lub lim tiam lossis siab dua) kom ua tiav qhov sib npaug ntawm kev ua tau zoo thiab thev taus.

3. ** Hloov kho Dosage ":

- Cov koob tshuaj tuaj yeem nce ntxiv raws li tus neeg mob cov lus teb, kev kam rau siab, thiab cov hom phiaj tswj glycemic.

- Qhov siab tshaj plaws koob tshuaj pom zoo yog feem ntau 15 mg / lub lim tiam, tab sis cov regimen yuav tsum tau kho los ntawm tus kws kho mob raws li tus neeg mob tus mob.

4. "Qhov chaw txhaj tshuaj **:

- Kev txhaj tshuaj subcutaneous tuaj yeem muab rau hauv plab, ncej puab lossis sab caj npab, nrog rau cov chaw txhaj tshuaj sib txawv xaiv txhua lub lim tiam kom tsis txhob muaj qhov khaus hauv zos.

### **Notes**

1. **Contraindications**:

- Cov neeg mob uas muaj cov qog nqaij hlav cancer qog nqaij hlav cancer lossis tsev neeg zaj keeb kwm ntawm tus kabmob.

- Cov neeg mob muaj ntau cov endocrine noppyria syndrome hom II.

- Cov neeg mob uas muaj kev cuam tshuam rau kev tu siab lossis nws cov khoom xyaw.

2. **Cov teebmeem tshwm sim ntau**:

- Cov plab zom mov tsis xis nyob xws li xeev siab, ntuav, raws plab, thiab cem quav.

- Kev Khomob Loj Hlob (tshwj xeeb tshaj yog thaum siv hauv kev sib xyaw nrog lwm cov ntshav qab zib kom txo qis).

- Cov chaw tawm tshiab me me.

3. **Kev siv sib xyaw nrog lwm yam tshuaj**:

- Nws tuaj yeem siv sib xyaw ua ke nrog lwm cov ntshav qab zib (xws li manformin, sglt {{2} Yuav tsum tau them rau qhov kev pheej hmoo ntawm hypoglycemia.

4. **Cev xeeb tub thiab lactation**:

- Tsis pom zoo siv los ntawm cov poj niam cev xeeb tub los yog pub niam mis. Nrog rau tus kws kho mob txog qhov xwm txheej tshwj xeeb.

### ** Lus xaus **

Tirzepatide yog qhov kev xav tau zoo tshaj plaws nrog cov ntshav qab zib muaj kev tiv thaiv kev kho mob thiab cov kev kho hnyav rau cov neeg mob ntshav qab zib hom 2 thiab cov neeg rog. Txawm li cas los xij, kev siv cov tshuaj yuav tsum nruj me ntsis ua raws tus kws kho mob cov lus qhia thiab saib xyuas cov piam thaj hauv qab zib thiab cov ntsuas kev nyab xeeb kom ntseeg tau tias kev kho mob thiab kev nyab xeeb zoo.

Tirzepatide yog ib qho tshuaj tiv thaiv kab mob ntshav qab zib tshiab uas muaj ntau yam sib txawv thiab muaj txiaj ntsig zoo hauv kev kho mob. HEPIUS-branded Tirzepatide ntxiv txhim khu kev ua tau zoo thiab kev lag luam kev sib tw ntawm cov tshuaj no los ntawm nws txoj kev tshawb fawb thiab kev tsim kho tshiab thiab kev tsim khoom zoo hauv kev kho mob ntshav qab zib thiab cov kab mob metabolic. Cov hauv qab no yog cov lus qhia ntxaws ntxaws txog qhov zoo ntawm HEPIUS hom Tirzepatide:

### ** 1. Tsis zoo ntawm cov tshuaj lub tshuab ntawm kev ua **

Tirzepatide yog dual receptor agonist ntawm GLP-1 (glucagon-zoo li peptide-1) thiab GIP (glucose-dependent insulinotropic polypeptide). Piv nrog rau cov tshuaj ib txwm ua haujlwm hypoglycemic, nws muaj cov txiaj ntsig hauv qab no:

- **Dual-target synergistic effect**: Activates GLP-1 thiab GIP receptors ib txhij, txhim kho cov nyhuv hypoglycemic.

- ** Txhim kho insulin kev zais cia **: Txhawb nqa cov zais ntawm insulin los ntawm cov hlwb pancer, thaum inhibiting lub zais ntawm glucagon los ntawm pancreatic cancer.

- ** Txo kev ntxhov siab ntawm pancreatic cell **: Tiv thaiv pancreatic islet muaj nuj nqi thiab ncua kev mob ntshav qab zib.

### ** 2. Cov teebmeem hauv tsev kho mob tseem ceeb **

Tirzepatide tau pom tias tseem ceeb ua tau zoo hauv ntau qhov chaw kuaj mob, xws li qhov tshaj tawm cov kev sim siab, suav nrog:

- ** Dua cov tshuaj tua cov ntshav qab zib zoo dua ** nrog rau cov tshuaj tua ntshav ntxiv, thiab qee tus neeg mob tuaj yeem ua tiav cov ntshav qab zib kom ze rau cov ntshav qab zib tsis yog.

- ** Cov txiaj ntsig zoo tswj hwm qhov hnyav **: Tirzepatide tsis yog tsuas yog muaj cov txiaj ntsig zoo ntawm cov ntshav qab zib, tab sis kuj tuaj yeem txo lub cev hnyav los ntawm kev tswj kev qab los noj mov thiab txhawb cov rog decomposition. Qee tus neeg mob tuaj yeem poob ntau dua 20% ntawm lawv qhov hnyav tom qab 12-18 lub hlis ntawm kev kho mob.

- ** Kev Tiv Thaiv Kab Mob plawv **: Kev tshawb fawb tau pom tias Tirzepatide txo qhov kev pheej hmoo ntawm cov kab mob plawv (xws li mob plawv, mob stroke, thiab lwm yam), tshwj xeeb tshaj yog rau cov neeg mob ntshav qab zib uas muaj kev pheej hmoo ntawm cov kab mob plawv.

### ** 3. Efficient persistence **

Tirzepatide yog siv raws li kev txhaj tshuaj ib zaug ib lub lim tiam. Qhov no ntev-acting txhaj mechanism:

- Txo qhov zaus ntawm cov tshuaj rau cov neeg mob thiab txhim kho kev ua raws cai.

- Tso tshuaj yeeb tshuaj tu cev tsis tu ncua thiab stabably kom tsis txhob muaj ntshav qab zib hloov pauv.

- Rau cov neeg mob ntawm kev kho mob mus sij hawm ntev, lub neej zoo tuaj yeem txhim kho tau zoo.

### ** 4. Hepius hom kev hloov tshiab **

Raws li tus tsim tawm thiab tsim tawm ntawm Tirzepatide, HEPIUS hom muaj cov hauv qab no tshwj xeeb kev sib tw zoo hauv kev ua lag luam los ntawm cov txheej txheem tshwj xeeb thiab kev tswj xyuas nruj:

- ** ** High kev ua si thiab kev ua haujlwm siab dua **: Hepius siv cov hluavtaws siab tshaj lij kom ntseeg tau tias cov kev ua kom siab ntawm Tirzepatide thiab txo cov kev mob tshwm sim.

- ** Nkag mus tau thiab them taus **: Muab piv nrog lwm hom, hepius tau zoo tshaj plaws cov nqi ntau lawm, thiab muab cov neeg mob uas muaj pheej yig dua.

- ** Khoom Stability **: Hepius cov khoom lag luam Tirzepatide qhia tau muaj zog dua thaum lub sijhawm khaws khoom thiab kev thauj mus los, thiab haum rau ntau yam chaw ua lag luam.

- ** QIB TSHAWB HAUS COV KEV UA LUAM NETWORKOUTTING Network Enabtive Tirzepatide kom sai li sai tau npog lub ntiaj teb kev ua lag luam thiab ua tau raws li cov neeg mob hauv ntiaj teb thiab tau raws li cov neeg mob xav tau ntau dua.

### 5. Ntau yam kev qhia **

Ntxiv nrog rau nws cov txiaj ntsig tseem ceeb hauv kev kho mob ntshav qab zib hom 2, Tirzepatide kuj tseem qhia tau tias muaj peev xwm siv tau rau hauv thaj chaw hauv qab no:

- ** Kev Kho Mob Obesity **: Tirzepatide tau raug tshawb fawb ntau los ua cov tshuaj tswj qhov hnyav rau cov neeg mob rog uas muaj peev xwm ua tau zoo dua lwm cov tshuaj tam sim no hauv khw.

- **Cov kab mob uas tsis yog-alcoholic fatty siab (NAFLD)**: Cov kev tshawb fawb ua ntej tau pom tias Tirzepatide tuaj yeem txhim kho hepatic steatosis thiab dhau los ua kev kho mob tshiab rau NAFLD thiab tsis muaj dej cawv steatohepatitis (NASH).

- **Ntau yam kab mob metabolic**: Kev tswj hwm ntawm cov teeb meem xws li kub siab, dyslipidemia, thiab lwm yam.

### ** 6. Txhim kho tus neeg mob kev paub **

Hepius hom tirzepatide yog cov neeg mob-centric thiab tsom rau kev ua kom zoo rau tus neeg mob kev paub:

- ** Kev txhaj tshuaj tua tau yooj yim **: Nruab nrog ib qho yooj yim tsis siv neeg txhaj tshuaj kom txhim kho kev tiv thaiv kev noj tshuaj.

- ** Txo cov kev phiv tsis zoo**: HEPIUS txo qhov tshwm sim ntawm qhov tshwm sim tsis zoo xws li xeev siab thiab ntuav los ntawm kev txhim kho cov mis.

WhatsApp / Telegram: +852 6749 2648

Gmail:lucasraws207@gmail.com

Skype: Nyob: .cid.8F21DC7FC6621BA7

Cim npe nrov: Hepius Tirzepatide 500mcg CAS: {{{}}}}}} {{{{} Cov neeg tsim khoom, cov chaw tsim khoom, Hoobkas